Last reviewed · How we verify

NCT04531319

Immune Cell Subgroups in Covid 19 Patients

Completed Last updated 12 January 2021
What this trial tests

trial testing Flow cytometric analysis in Covid19 in 50 participants. Completed in 1 October 2020.

Timeline
15 August 2020
Primary endpoint
1 October 2020
1 October 2020

Quick facts

Lead sponsorIstanbul Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date15 August 2020
Primary completion1 October 2020
Estimated completion1 October 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Training and Research Hospital

Who can join

Adults 18 to 80, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19, spreading rapidly all over the world, causes serious morbidity and mortality. In severe COVID-19 infections, after pulmonary inflammation, cardiovascular organ failure, cytokine storm, hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and isolated organ failure turns into multi-organ failure. It is noteworthy that it causes lymphopenia in patients. In studies conducted, the effects of Covid-19 on the immune system were evaluated with limited parameters. In addition, no study evaluating the effect of this disease on the immune system has been published in our country.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Natural killer cells in COVID-19: from infection, to vaccination and therapy.
    Zafarani A, Razizadeh MH, Pashangzadeh S, Amirzargar MR, et al · · 2023 · cited 24× · PMID 36936055 · DOI 10.2217/fvl-2022-0040
  2. The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
    Hernández-Blanco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, et al · · 2025 · cited 1× · PMID 39877904 · DOI 10.1016/j.isci.2024.111698

Verify or expand the search:

Other trials of Flow cytometric analysis

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Istanbul Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04531319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing